Pacira Pharmaceuticals yesterday reported Q4 EXPAREL® sales of $67.2m and FY2015 sales of $239.9m, slightly ahead of our $236m forecast. Following the favourable conclusion of its discussions with the FDA, Pacira remains positive on the prospects for EXPAREL® and we continue to expect strong growth in product sales, supported by a broader label (incl. oral surgery) and additional indications over time. We continue to expect Skyepharma to receive an $8m milestone from Pacira in 2016 (for net sale ....
